IPG model
mRNA drug discovery platform through specialization and collaboration
*1 IP Gaia: Licensing intellectual property to pharmaceutical companies and other companies engaged in manufacturing and selling pharmaceutical products.
*2 ADDP (Axcelead Drug Discovery Partners): Drug discovery solution provider
*3 Arcalis: Drug discovery support for mRNA medicines and vaccines, contract development and manufacturing business (CDMO)
State-of-the-art IP generation platform for mRNA medicine with excellent partners
In May 2023, our business alliances with Axcelead and IPGaia were upgraded to capital and business alliances. The alliance with these companies has created a one-stop mRNA drug discovery platform from the start of a drug discovery project to IP licensing including manufacturing and non-clinical development. This combination of stateof- the-art expertise enables NanoCarrier to rapidly generate high quality mRNA drug candidates in great demand by pharmaceutical companies, even with a small number of staff.
Our financial strength and our open attitude to innovation without insisting on proprietary technologies set us apart from our competitors.
NanoCarrier has sufficient funds to generate mRNA medicine IPs. We will use these funds to identify the needs, combine the most appropriate technologies for each mRNA drug candidate, and create IP. To achieve this, we are also willing to incorporate various technologies from outside the company using our own network and that of our partners.